WallStreetZenWallStreetZen

NYSEMKT: PTN
Palatin Technologies Inc Stock

$1.20-0.04 (-3.23%)
Updated Nov 1, 2024
Palatin Technologies shares are trading... find out Why PTN Price Moved with a free WallStreetZen account
Why Price Moved
PTN Price
$1.20
Fair Value Price
N/A
Market Cap
$23.46M
52 Week Low
$0.68
52 Week High
$5.65
P/E
-0.59x
P/B
-210.39x
P/S
6.38x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.49M
Earnings
-$29.74M
Gross Margin
97.8%
Operating Margin
-661.88%
Profit Margin
-662.3%
Debt to Equity
-97.35
Operating Cash Flow
-$31M
Beta
1.25
Next Earnings
Nov 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A

PTN Overview

Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.

Zen Score

–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PTN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PTN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PTN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
PTN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more PTN due diligence checks available for Premium users.

Be the first to know about important PTN news, forecast changes, insider trades & much more!

PTN News

Valuation

PTN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.59x
Industry
-103.77x
Market
22.22x

PTN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-210.39x
Industry
5.8x

PTN's financial health

Profit margin

Revenue
$350.0k
Net Income
-$8.3M
Profit Margin
-2,357.3%
PTN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PTN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$10.7M
Liabilities
$10.9M
Debt to equity
-97.35
PTN's short-term assets ($9.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PTN's short-term assets ($9.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PTN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PTN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.5M
Investing
-$4.9k
Financing
$6.0M
PTN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PTN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
PTN$23.46M-3.23%-0.59x-210.39x
ATHA$23.29M+41.59%-0.20x0.28x
IBIO$23.06M+3.09%-0.41x1.08x
NRSN$22.93M+1.60%-3.74x-13.46x
TPST$22.91M-0.66%-0.57x1.35x

Palatin Technologies Stock FAQ

What is Palatin Technologies's quote symbol?

(NYSEMKT: PTN) Palatin Technologies trades on the NYSEMKT under the ticker symbol PTN. Palatin Technologies stock quotes can also be displayed as NYSEMKT: PTN.

If you're new to stock investing, here's how to buy Palatin Technologies stock.

What is the 52 week high and low for Palatin Technologies (NYSEMKT: PTN)?

(NYSEMKT: PTN) Palatin Technologies's 52-week high was $5.65, and its 52-week low was $0.68. It is currently -78.76% from its 52-week high and 76.47% from its 52-week low.

How much is Palatin Technologies stock worth today?

(NYSEMKT: PTN) Palatin Technologies currently has 19,548,167 outstanding shares. With Palatin Technologies stock trading at $1.20 per share, the total value of Palatin Technologies stock (market capitalization) is $23.46M.

Palatin Technologies stock was originally listed at a price of $1,470.00 in Dec 31, 1997. If you had invested in Palatin Technologies stock at $1,470.00, your return over the last 26 years would have been -99.92%, for an annualized return of -23.93% (not including any dividends or dividend reinvestments).

How much is Palatin Technologies's stock price per share?

(NYSEMKT: PTN) Palatin Technologies stock price per share is $1.20 today (as of Nov 1, 2024).

What is Palatin Technologies's Market Cap?

(NYSEMKT: PTN) Palatin Technologies's market cap is $23.46M, as of Nov 2, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Palatin Technologies's market cap is calculated by multiplying PTN's current stock price of $1.20 by PTN's total outstanding shares of 19,548,167.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.